Myokines as Possible Therapeutic Targets in Cancer Cachexia

Area of Science:

• Biochemistry
• Oncology
• Endocrinology

Background:

• Cachexia is a severe cancer-associated syndrome characterized by inflammation and involuntary weight loss, significantly impacting patient quality of life and treatment outcomes.
• Despite its prevalence and detrimental effects, cachexia remains underestimated and inadequately treated, necessitating further research into its underlying mechanisms.
• Skeletal muscle functions as an endocrine organ, releasing signaling molecules called myokines that mediate communication with other bodily systems.

Purpose of the Study:

• To review the role of myokines in cancer cachexia.
• To identify specific myokines with potential as biomarkers for diagnosis and prognosis.
• To explore the therapeutic potential of myokines in managing cancer cachexia.

Main Methods:

• Literature review of scientific articles on cachexia and myokines.
• Analysis of the biological functions and signaling pathways of key myokines.
• Identification of myokines implicated in cancer-associated wasting.

Main Results:

• Several myokines, including myostatin, irisin, myonectin, decorin, fibroblast growth factor 21, and interleukins (IL-6, IL-8, IL-15), are implicated in cancer cachexia.
• These myokines play roles in regulating protein and energy balance, inflammation, and muscle metabolism.
• Their dysregulation contributes to the pathophysiology of cachexia.

Conclusions:

• Myokines represent promising avenues for understanding and potentially treating cancer cachexia.
• Specific myokines may serve as valuable biomarkers for early detection and monitoring of cachexia.
• Targeting myokine pathways could offer novel therapeutic strategies to combat cancer-induced muscle wasting and improve patient survival.